Celon Pharma SA (WAR:CLN) — Stock Price
Celon Pharma SA (WAR:CLN) is currently trading at zł20.70 PLN, up 1.22% today. Over the past 52 weeks, shares have ranged between zł18.82 and zł23.50. This page tracks Celon Pharma SA's live share price on the WAR exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Celon Pharma SA (CLN) market capitalisation.
Celon Pharma SA (CLN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Celon Pharma SA's daily closing share price and trading volume on the WAR exchange over the past year, giving a clear view of recent price momentum and liquidity.
Celon Pharma SA Income Statement — Revenue, Profit & Earnings by Year
Celon Pharma SA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | zł176.62 Million | zł213.92 Million | zł161.91 Million | zł196.09 Million | zł157.45 Million |
| Cost of Revenue | zł63.17 Million | zł66.82 Million | zł66.46 Million | zł61.72 Million | zł32.01 Million |
| Gross Profit | zł113.45 Million | zł147.10 Million | zł95.45 Million | zł134.37 Million | zł107.26 Million |
| Research & Development | — | zł680.00K | zł680.00K | zł49.05 Million | zł42.25 Million |
| SG&A | — | — | — | zł37.38 Million | zł10.95 Million |
| Total Operating Expenses | zł150.26 Million | zł174.34 Million | zł14.12 Million | zł144.82 Million | zł124.48 Million |
| Operating Income | zł-36.81 Million | zł-27.24 Million | zł-69.76 Million | zł-10.45 Million | zł-3.67 Million |
| EBITDA | zł14.96 Million | zł32.71 Million | zł9.32 Million | zł27.81 Million | zł30.37 Million |
| EBIT | zł-36.90 Million | zł-17.30 Million | zł-34.77 Million | zł-13.53 Million | zł-4.17 Million |
| Interest Expense | zł2.47 Million | zł2.67 Million | zł1.67 Million | zł1.55 Million | zł1.42 Million |
| Income Before Tax | zł-39.37 Million | zł-19.97 Million | zł-36.45 Million | zł-15.09 Million | zł-5.59 Million |
| Income Tax Expense | zł-4.92 Million | zł8.16 Million | zł2.83 Million | zł-3.48 Million | zł4.67 Million |
| Net Income | zł-34.45 Million | zł-28.12 Million | zł-39.28 Million | zł-11.61 Million | zł-917.00K |
Celon Pharma SA Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Celon Pharma SA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | zł457.46 Million | zł543.79 Million | zł569.31 Million | zł608.93 Million | zł707.14 Million |
| Total Current Assets | — | zł160.43 Million | zł189.75 Million | zł237.58 Million | zł278.70 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | zł48.24 Million | zł82.18 Million | zł81.72 Million | zł79.75 Million |
| Net Receivables | — | zł44.01 Million | zł48.24 Million | zł33.70 Million | zł27.25 Million |
| Inventory | — | zł29.22 Million | zł26.41 Million | zł38.38 Million | zł23.37 Million |
| Property, Plant & Equipment | — | — | — | — | zł316.57 Million |
| Goodwill | — | — | — | zł-5.32 Million | — |
| Total Liabilities | zł94.21 Million | zł98.59 Million | zł123.75 Million | zł129.29 Million | zł153.14 Million |
| Total Current Liabilities | zł63.27 Million | zł87.12 Million | zł86.34 Million | zł116.44 Million | zł86.36 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | zł8.65 Million | zł-6.77 Million | zł-56.08 Million | zł-132.88 Million |
| Total Stockholder Equity | zł363.25 Million | zł445.21 Million | zł445.56 Million | zł479.65 Million | zł554.00 Million |
| Retained Earnings | — | zł-114.96 Million | zł-108.64 Million | zł-119.79 Million | zł-91.67 Million |
Celon Pharma SA Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Celon Pharma SA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | zł23.85 Million | zł-11.34 Million | zł-8.31 Million | zł-4.70 Million | zł43.95 Million |
| Capital Expenditures | zł0.00 | zł22.79 Million | zł32.81 Million | zł33.91 Million | zł41.35 Million |
| Free Cash Flow | zł23.85 Million | zł-34.13 Million | zł-41.13 Million | zł-38.61 Million | zł2.60 Million |
| Investing Cash Flow | — | zł-7.49 Million | zł-21.64 Million | zł-31.47 Million | zł-121.05 Million |
| Financing Cash Flow | — | zł13.32 Million | zł-20.59 Million | zł-28.72 Million | zł180.91 Million |
| Dividends Paid | — | zł4.08 Million | zł4.59 Million | zł14.80 Million | zł3.15 Million |
| Stock-Based Compensation | — | zł1.56 Million | zł0.00 | zł309.00K | zł174.00K |
| Depreciation | — | zł51.86 Million | zł50.02 Million | zł44.09 Million | zł41.34 Million |
| Change in Cash | zł-7.54 Million | zł-5.51 Million | zł-50.54 Million | zł-64.89 Million | zł103.82 Million |
Celon Pharma SA Earnings History — EPS Actual vs. Analyst Estimates
Track Celon Pharma SA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 19, 2026 | 3.06 | — | — |
| Dec 31, 2025 | -0.46 | — | — |
| Sep 30, 2025 | 0.07 | — | — |
| Sep 17, 2025 | -0.62 | — | — |
| May 21, 2025 | -0.47 | — | — |
| Nov 20, 2024 | 1.06 | — | — |
| Jun 30, 2024 | -0.16 | — | — |
| May 22, 2024 | -0.31 | — | — |